Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

212
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
212
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

253
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
253
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

212
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
212
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

166
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
166

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection.

Alimentary pharmacology & therapeutics·2026
Same author

Global Trends in National Alcohol Control Policies Between 2010-2019.

JHEP reports : innovation in hepatology·2026
Same author

Spatial and Molecular Progression of Neural Progenitor Cells in the Developing Human Dentate Gyrus.

bioRxiv : the preprint server for biology·2026
Same author

Steatotic liver disease in Latin America: current views and perspectives.

Nature reviews. Gastroenterology & hepatology·2026
Same author

Racial Disparities in Clinical and Cardiometabolic Outcomes Among Patients with Alcohol-Associated Liver Disease.

Digestive diseases and sciences·2026
Same author

Serum HMGB1 and Alcohol-Related Liver Disease.

Journal of clinical medicine·2026
Same journal

Association of metabolic dysfunction-associated steatotic liver disease onset age with risk of incident type 2 diabetes.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

Randomized trial comparing 5-year follow-up of first-line infliximab to conventional therapy in paediatric Crohn's disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

What Does "Non-Intensive Surveillance" Mean After Curative ESD for Low-Risk T1 Colorectal Cancer?

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

Methodological and Reporting Caveats in Evaluating Facility Detection Metrics for Barrett's Esophagus.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Adults: Expert Review.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
See all related articles

Related Experiment Video

Updated: Jan 15, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.6K

Placebo Rates in Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials: A Systematic Review and

Francisco Idalsoaga1, Luis Antonio Díaz2, Saleh Alghsoon3

  • 1Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|October 11, 2025
PubMed
Summary
This summary is machine-generated.

High placebo response rates in metabolic dysfunction-associated steatohepatitis (MASH) trials are common. This meta-analysis quantifies these rates, offering insights for future clinical trial design in MASH drug development.

Keywords:
CirrhosisMASHMASLDMetabolic Dysfunction–Associated SteatohepatitisMetabolic Dysfunction–Associated Steatotic Liver DiseaseNAFLDNonalcoholic Fatty Liver Disease

More Related Videos

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.6K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

699

Related Experiment Videos

Last Updated: Jan 15, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.6K
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.6K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

699

Area of Science:

  • Hepatology
  • Clinical Trial Design
  • Pharmacology

Background:

  • High placebo response rates present a significant challenge in clinical trials for metabolic dysfunction-associated steatohepatitis (MASH).
  • Understanding placebo response variability is crucial for accurate assessment of drug efficacy in MASH.

Purpose of the Study:

  • To quantify placebo response rates in MASH clinical trials.
  • To identify patient and trial design factors influencing placebo response.

Main Methods:

  • A systematic meta-analysis of placebo-controlled trials for MASH interventions.
  • Searched MEDLINE, Embase, and CENTRAL up to May 2025.
  • Pooled placebo response rates using random-effects models and meta-regression analysis.

Main Results:

  • Pooled MASH resolution without fibrosis worsening in non-cirrhotic placebo patients was 11% (95% CI, 8%-14%).
  • No significant patient or trial characteristics were associated with placebo response.
  • Secondary outcomes showed elevated rates for normal ALT (12%) and hepatic fat reduction (22% absolute, 19% relative).

Conclusions:

  • Placebo response rates in MASH trials are substantial but vary by outcome.
  • Findings provide critical data to inform and optimize future MASH clinical trial designs.